mRNA melanoma vaccine cuts relapses by 42% in phase 3 trial
Moderna and Merck's mRNA vaccine reduced the risk of relapse in high-risk melanoma by 42% in phase 3. What is still missing for Mexico and its regulatory path.
The personalized mRNA vaccine intismeran autogene reduced the risk of relapse or death by 42% in patients with high-risk melanoma that had already been operated on, according to phase 3 results from the INTerpath-001 trial, presented on October 24, 2026 at the congress of the European Society for Medical Oncology (ESMO) in Madrid. The study included 1,137 patients, with a median follow-up of 24.6 months.
The Merck and Moderna combination was tested with pembrolizumab (Keytruda), Merck's best-selling immunotherapy, against Keytruda alone, according to Merck's press release. At two years, 82.2% of patients who received the vaccine remained cancer-free, compared with 70.0% in the control group. Scientific American noted that overall survival data do not yet exist, a point that separates this result from a completed change in the standard of care. For health operators in Mexico, oncology clinics, insurers and healthtechs, the practical question is one of capacity: the vaccine is manufactured from a sample of each patient's tumor.
The evaluated regimen administered 1 mg of intismeran every three weeks, up to nine doses, starting at week 13 after surgery, plus Keytruda 400 mg every six weeks for up to nine cycles. The benefit concentrated after six months of immunization: the sensitivity analysis reported a 58% reduction in the risk of relapse or death (HR 0.42). Grade 3 to 5 adverse events were 14.2% with the combination and 13.4% with Keytruda alone, with pyrexia and injection-site pain among the most frequent. Merck reported that it is holding talks with regulatory authorities, and a Reuters dispatch published by The Standard reported that the pharmaceutical companies expect a U.S. launch in 2027.
None of this amounts to availability in Mexico: the pharmaceutical companies have not announced a registration application with COFEPRIS or a price, and production requires tumor sequencing and made-to-order manufacturing. The data leave three fronts for oncology operators to monitor: the date of the regulatory submission, the maturation of overall survival, and the cold-chain logistics that a personalized biologic demands.
This article was written with the assistance of artificial intelligence from verified sources and reviewed by a human editor before publication.
Sources
- Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA at ESMO 2026 Presidential Symposium
- Here's what the new Merck-Moderna mRNA cancer vaccine data actually show
- Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall